Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
5.95 USD
4.75%
Market Closed
Updated:
May 15, 2024
Editas Medicine Inc
Net Change in Cash
|
Editas Medicine Inc
Net Change in Cash Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Change in Cash Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Net Change in Cash
-$59.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
$3.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
$673m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-17%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$21.9B
|
CAGR 3-Years
-140%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$139.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Editas Medicine Inc's Net Change in Cash?
Net Change in Cash
-59.8m
USD
-59.8m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Net Change in Cash amounts to -59.8m USD.
What is Editas Medicine Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
0%
0%
Over the last year, the Net Change in Cash growth was 27%.
You don't have any saved screeners yet
